Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 11:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 37,486 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phase 2 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49

NCT01658800
View directory record Official record
Conditions
Influenza
Interventions
VAX161C vaccine
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
South Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 23, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Results available

A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

NCT01187407
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
LY2216684, Placebo, SSRI
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chino, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 23, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy

NCT02296892
View directory record Official record
Conditions
Bronchoscopy
Interventions
Remimazolam, Placebo, Midazolam
Drug
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Brandon, Florida • Sun City Center, Florida • Michigan City, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 23, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

NCT01297270
View directory record Official record
Conditions
Hepatitis C
Interventions
BI201335, PegIFN/RBV, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
78
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 23, 2026, 11:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye

NCT01319773
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
cyclosporine ophthalmic emulsion Formulation A, cyclosporine ophthalmic emulsion Formulation B, cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%, cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%, cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Oct 23, 2026, 11:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Method of Fish Oil Administration on Patient Compliance

NCT01471366
View directory record Official record
Conditions
Adverse Effects
Interventions
Frozen capsule, Capsule with food, Capsule without food, Capsule with milk
Dietary Supplement
Lead sponsor
University of Mississippi, Oxford
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 23, 2026, 11:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation

NCT03130556
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Glasdegib, High Fat, High Calorie Meal, Rabeprazole
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 23, 2026, 11:45 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression

NCT03460756
View directory record Official record
Conditions
Depressive Disorder, Depression, Depression, Postpartum, Behavioral Symptoms, Mood Disorders, Mental Disorder, Pregnancy Complications, Postpartum Blues, PPD, Postpartum Disorder
Interventions
Ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
33
States / cities
Glendale, California • Lemon Grove, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 23, 2026, 11:45 PM EDT
Completed Phase 1 Interventional Results available

Computer Vision System for the Blind Veteran

NCT00920231
View directory record Official record
Conditions
Blindness
Interventions
initial system, modified system
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Decatur, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 23, 2026, 11:45 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults

NCT07757802
View directory record Official record
Conditions
HIV
Interventions
DV901-NP, DV902-NP, CH505 TF mRNA-gp160, CH505 w24 mRNA-gp160, ACU-026-001-1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
8
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 11:45 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma

NCT01083602
View directory record Official record
Conditions
Relapsed and Bortezomib Refractory Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse
Interventions
panobinostat, bortezomib, dexamethasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Stanford, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 23, 2026, 11:45 PM EDT
Recruiting Phase 2 Interventional

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT04169737
View directory record Official record
Conditions
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions
Acalabrutinib, Obinutuzumab, Venetoclax
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 11:45 PM EDT
Completed Not applicable Interventional Results available

Technology for MAT in Primary Care - Phase 2

NCT05017272
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Opioid Addiction Recovery Support Software Platform
Other
Lead sponsor
Q2i, LLC
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 23, 2026, 11:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts

NCT02402595
View directory record Official record
Conditions
Healthy
Interventions
AVP-923, AVP-786, Itraconazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 23, 2026, 11:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease

NCT05644977
View directory record Official record
Conditions
Healthy Participants, Alzheimer's Disease Dementia
Interventions
Emraclidine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
11
States / cities
Cypress, California • San Diego, California • Hialeah, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 23, 2026, 11:45 PM EDT
Recruiting Phase 1 Interventional

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

NCT07426757
View directory record Official record
Conditions
Advanced Malignancies, Advanced Cancer
Interventions
PF-07994525, Midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
24
States / cities
Denver, Colorado • New Haven, Connecticut • North Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 11:45 PM EDT
Completed Phase 2 Interventional

GliaSite 1-3 Mets Study

NCT00589212
View directory record Official record
Conditions
Brain Metastases
Interventions
GliaSite Radiation Therapy System
Device
Lead sponsor
Hologic, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 11, 2008 · Synced Oct 23, 2026, 11:45 PM EDT
Completed Phase 3 Interventional

Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

NCT00036556
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Atrasentan
Drug
Lead sponsor
Abbott
Industry
Eligibility
19 Years and older · Male only
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
94
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2007 · Synced Oct 23, 2026, 11:45 PM EDT
Completed Phase 2 Interventional Results available

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

NCT00722553
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Bladder Cancer, Bladder Neoplasm
Interventions
Pralatrexate Injection, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Tucson, Arizona • Atlanta, Georgia • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 23, 2026, 11:45 PM EDT
Completed Phase 3 Interventional Results available

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

NCT00094653
View directory record Official record
Conditions
Melanoma, Metastases
Interventions
MDX-010 (anti-CTLA4) monoclonal antibody, MDX-1379 (gp100) Melanoma Peptide Vaccine
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,783 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
110
States / cities
Tucson, Arizona • Duarte, California • Encinitas, California + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Oct 23, 2026, 11:45 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
RO7795081, Semaglutide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Tucson, Arizona • Lake Forest, California • Rancho Cucamonga, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 11:45 PM EDT
Completed Early Phase 1 Interventional

TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia

NCT04518345
View directory record Official record
Conditions
Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions
Azacitidine, Dubermatinib
Drug
Lead sponsor
Uma Borate
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 23, 2026, 11:45 PM EDT
Completed Phase 3 Interventional

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

NCT05568095
View directory record Official record
Conditions
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Interventions
Domvanalimab, Zimberelimab, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
31
States / cities
Los Angeles, California • Orange, California • Santa Monica, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 23, 2026, 11:45 PM EDT
Recruiting Phase 3 Interventional

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

NCT06064877
View directory record Official record
Conditions
Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Ficlatuzumab, Cetuximab, Placebo
Biological · Other
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Gilbert, Arizona • Tucson, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 23, 2026, 11:45 PM EDT